<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05000658</url>
  </required_header>
  <id_info>
    <org_study_id>RC21_0148</org_study_id>
    <nct_id>NCT05000658</nct_id>
  </id_info>
  <brief_title>Efficacy of Soluble Dexamethasone in Refractory Sciatica</brief_title>
  <acronym>Dexhia</acronym>
  <official_title>Efficacy of Soluble Dexamethasone by Echo-guided Infiltration Through the Sacrococcygeal Hiatus in Refractory Sciatica: a Prospective Randomised Double-blind Study Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3 prospective randomised double-blind study versus placebo, measuring the&#xD;
      efficacy of soluble Dexamethasone by echo-guided infiltrations through the sacro-coccygeal&#xD;
      hiatus in intractable sciatica&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Injection of 4ml of Dexamethasone Phosphate Soluble or 4ml of saline solution depending on&#xD;
      the randomisation arm&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness assessed by classical global algo-functional index: OSWESTRY</measure>
    <time_frame>Week 3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Value of Eva scale for evaluated effectiveness on lower back pain</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of Eva scale for evaluated effectiveness on lower back pain</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of Eva scale for evaluated effectiveness on lower back pain</measure>
    <time_frame>Week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of Eva scale for evaluated effectiveness on lower back pain</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of Eva scale for evaluated effectiveness on lower back pain</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of Eva scale for evaluated effectiveness on sciatic pain</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of Eva scale for evaluated effectiveness on sciatic pain</measure>
    <time_frame>Week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of Eva scale for evaluated effectiveness on sciatic pain</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of Eva scale for evaluated effectiveness on sciatic pain</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days off work</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of score to scale Oswestry</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of score to scale Oswestry</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of score to scale Oswestry</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of score to scale Oswestry</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of score to SF36 self questionnaires</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of score to SF36 self questionnaires</measure>
    <time_frame>Week 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of score to SF36 self questionnaires</measure>
    <time_frame>Week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of score to SF36 self questionnaires</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Value of score to SF36 self questionnaires</measure>
    <time_frame>Month 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of second injections required</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients undergoing secondary surgery</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Result of Clinical parameters</measure>
    <time_frame>week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Result of Imaging parameters</measure>
    <time_frame>week 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of secondary effects</measure>
    <time_frame>Month 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Sciatica</condition>
  <arm_group>
    <arm_group_label>group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HSC one injection of 4 mL soluble Dexamethasone phosphate (16 mg) (equivalent to 100 mg Prednisone), followed by up to 16 mL saline (depending on tolerance)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HSC one injection of 4mL of saline and then up to 16 mL of saline (depending on tolerance)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone phosphate</intervention_name>
    <description>HSC injection of 4mL</description>
    <arm_group_label>group A</arm_group_label>
    <arm_group_label>group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with sciatica of disc origin (radio-clinical concordance on MRI or CT)&#xD;
             postero-lateral&#xD;
&#xD;
          -  Duration of evolution greater than 3 weeks despite analgesic / AINS treatment, and&#xD;
             less than 3 months&#xD;
&#xD;
          -  EVA sciatica pain &gt; 4/10&#xD;
&#xD;
          -  Oswestry 30 at inclusion&#xD;
&#xD;
          -  Patient aged 18 years and older&#xD;
&#xD;
          -  Patient affiliated to a social security scheme&#xD;
&#xD;
          -  Patient able to understand the protocol and having signed an informed consent&#xD;
&#xD;
          -  Patient with an indication for corticosteroid infiltration in the context of their&#xD;
             pathology&#xD;
&#xD;
        Criteria for non-inclusion&#xD;
&#xD;
          -  Signs or risks of infection, in particular signs of virosis&#xD;
&#xD;
          -  Poor local skin condition&#xD;
&#xD;
          -  Anticoagulation with VKA or anti-Xa, or haemorrhagic disease&#xD;
&#xD;
          -  Neurological deficit &lt; 3/5 or signs of cauda equina irritation&#xD;
&#xD;
          -  Tarlov's cyst or low dural sac below week 4&#xD;
&#xD;
          -  Hypersensitivity to Lidocaine, Dexamethasone, or any of its excipients&#xD;
&#xD;
          -  Infiltration of the spine within the previous 3 months&#xD;
&#xD;
          -  Patient with bilateral sciatica&#xD;
&#xD;
          -  Patient with sciatica of osteoarthritic origin&#xD;
&#xD;
          -  Patients with chronic respiratory insufficiency&#xD;
&#xD;
          -  Pregnant or breastfeeding women or women refusing effective contraception until M3&#xD;
&#xD;
          -  Patient deprived of liberty or under legal protection (guardianship or curatorship)&#xD;
&#xD;
          -  Patient under court protection&#xD;
&#xD;
          -  Patients participating in another clinical research protocol involving a drug or&#xD;
             medical device&#xD;
&#xD;
          -  Patients unable to follow the protocol, as judged by the investigator&#xD;
&#xD;
          -  Patient refusing to participate in the study&#xD;
&#xD;
          -  Patient with clinically narrowed lumbar canal&#xD;
&#xD;
          -  Patient with polyneuropathy or myelopathy&#xD;
&#xD;
          -  Patient with sequelae of neuropathic pain&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maugars</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maugars</last_name>
    <phone>0240084820</phone>
    <email>yves.maugars@chu-nantes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maugar</last_name>
      <phone>0240084820</phone>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reluctant Sciatica, Infiltrations, Soluble Dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sciatica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

